Preparation containing fosthiazate and imidacloprid and application thereof
By combining thiazolylide and imidacloprid in pesticides, the microcapsule suspension-suspended agents are prepared, and the existing pesticide preparations have solved the problem of poor rapid effect and insufficient chemical stability in the prevention and control of root knot nematodes and puncture-type pests, thus achieving high efficiency of pesticides The prevention and control effect and stability have expanded the scope of use of pesticides.
Patent Information
- Application Number
- CN202411046892.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-01
- Publication Date
- 2024-11-19
AI Technical Summary
The existing pesticide preparations have problems of poor speed effect and insufficient chemical stability in the prevention and control of root knot nematodes and puncture pests, and the lack of the application of microcapsule suspension-suspended agents, which limits the scope and effect of pesticides.
Thiazolylide and imidacloprid as main components are used to prepare thiazolylide microcapsules by interfacial polymerization, and imidacloprid suspension agent is prepared in combination with wet grinding and crushing process to form microcapsule suspension-suspension agent, combining solvent oil, PEG400, TD I, Atlox 4913 , Lutenso l TO8, SAG1572, BI T preservative, magnesium aluminum silicate and xanthan gum and other components to form a stable microcapsule suspension suspension agent.
It realizes efficient coating and stability of thiazolyte microcapsules, has excellent suspension and coating rate, has good rapid-acting and sustainability, can effectively prevent and control root knot nematodes and pistachiosus, and expands pesticides Range of use.
Smart Images

Figure CN118975558A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to a pesticide preparation, and specifically relates to a preparation containing thiamethoxam and imidacloprid and an application thereof. Background Art
[0002] In recent years, pesticide controlled-release preparations have become an effective means to solve the problems existing in traditional pesticide preparations. Pesticide microencapsulation is an important part of pesticide controlled-release technology. Pesticide microencapsulation not only improves the physical and chemical stability of the active ingredients, but also increases the chemical stability of the active ingredients, reduces the frequency of pesticide use, controls the release of drug molecules, and prolongs the duration of drug efficacy. Microcapsule suspension-suspension concentrate ZC is a new dosage form, which is a stable suspension liquid preparation in which the active ingredients are dispersed in water in the form of microcapsules and solid particles. Microcapsules have the disadvantage of poor rapid effect in the early stage of release, which is not conducive to the prevention and control of sudden diseases and insect pests. The new microcapsule suspension-suspension concentrate will make up for the shortcomings of the microcapsule dosage form, give full play to the advantages of the microcapsule dosage form and suspension concentrate, and expand the scope of separate use of microcapsules and suspension concentrates, so that the microcapsule suspension-suspension concentrate has both rapid effect and long-lasting effect, so that the agent can protect plants from diseases and insect pests.
[0003] Thiazole is an organophosphorus nematicide with low toxicity, good rapid effect and long lasting effect. Its main mode of action is to inhibit the acetylcholinesterase of root-knot nematodes. It has contact and systemic effects. Nematodes die when they come into contact with thiazole in the soil or are absorbed into the roots of crops and kill the root-knot nematodes that invade the nodules of crops. Thiazole has upward conductivity, with strong conduction from roots to leaves, weak conduction from leaves to flowers, and basically no conduction from flowers to fruits. Therefore, it can control piercing-sucking pests at the same time.
[0004] Imidacloprid is a neonicotinoid insecticide with a broad spectrum, low toxicity and low residue. It can selectively act on the acetylcholine receptors in the insect nervous system, thereby destroying the normal conduction of the insect's central nervous system. Therefore, it has high insecticidal activity, especially against piercing-sucking mouthparts pests. It has contact, stomach poison and systemic effects.
[0005] CN113115790A discloses a composition, pesticide preparation and method for controlling root-knot nematodes, wherein two active ingredients, thiazolyl and imidacloprid, are combined, and the mechanisms of action are different in controlling root-knot nematodes and there is no cross-resistance. The combination of the two has an obvious synergistic effect. The formulation of the pesticide preparation is an aqueous emulsion, a wettable powder, a microemulsion, a suspension or a water-dispersible granule, and the microcapsule suspension-suspension concentrate and its preparation performance are not disclosed. In addition, no relevant product registrations of microcapsule suspensions of thiazolyl and imidacloprid were found on the China Pesticide Information Network. Summary of the invention
[0006] The object of the present invention is to provide a microcapsule suspension containing thiazolyl and imidacloprid and its application. The specific technical scheme is as follows:
[0007] A microcapsule suspension containing thiamethoxam and imidacloprid comprises the following ingredients in percentage by weight: 2-3% of thiamethoxam technical drug, 7-8% of imidacloprid technical drug, 8-12% of solvent oil 150#, 2-3.5% of TDI (toluene diisocyanate), 0.8-1.6% of PEG400, 2.5-4.5% of Atlox4913, 1-3% of Lutensol TO8, 0.05-0.15% of SAG1572, 0.05-0.15% of BI T preservative, 0.5-1.5% of magnesium aluminum silicate, 0.1-0.2% of xanthan gum and water to make up to 100%.
[0008] Preferably, the microcapsule suspension containing thiamethoxam and imidacloprid comprises the following ingredients in percentage by weight: 2.5% of thiamethoxam technical drug, 7.5% of imidacloprid technical drug, 10% of solvent oil 150#, 2.7% of TDI (toluene diisocyanate), 1.2% of PEG400, 3.5% of Atlox4913, 2.0% of Lutensol TO8, 0.1% of SAG1572, 0.1% of BIT preservative, 1% of magnesium aluminum silicate, 0.14% of xanthan gum and 100% of water.
[0009] The preparation method of the microcapsule suspension containing thiazolyl and imidacloprid comprises the following steps:
[0010] Step 1: Preparation of thiazole phosphine microcapsules: water phase preparation: dissolving dispersant Atlox 4913 in water as the water phase for standby use; oil phase preparation: dissolving thiazole phosphine, emulsifier Lutensol TO8 and capsule skin material TDI in solvent solvent oil 150# to form an oil phase for standby use; under high shear conditions, pouring the oil phase into the water phase at a uniform speed for shearing to form a stable oil-in-water (O / W) emulsion; transferring the stable emulsion to a three-necked flask, dissolving initiator PEG400 in water at the same time, and adding it dropwise to the emulsion at a uniform speed under stirring conditions for interfacial polymerization reaction. After the reaction is completed, thiazole phosphine microcapsules are obtained;
[0011] Step 2: preparing imidacloprid suspension concentrate: mixing imidacloprid, remaining dispersant At lox 4913, SAG1572, BIT preservative, magnesium aluminum silicate, and xanthan gum, and preparing thiamethoxam suspension concentrate by wet grinding and pulverization process;
[0012] Step 3: stir and mix thiazolyl microcapsules and imidacloprid suspension in equal mass ratios.
[0013] Compared with the prior art, the present invention achieves the following beneficial technical effects:
[0014] The thiazole phosphine microcapsules prepared by the present invention have good appearance and morphology and small particle size. In particular, when the emulsifier is Lutensol TO8 and the dispersant is Atlox 4913, the D50 of the thiazole phosphine microcapsules is 2.052 μm and the coverage rate is 95.21%. That is, the highly effective chlorfenapyr microcapsules prepared by the interfacial polymerization method have good appearance and morphology and high coverage rate.
[0015] The microcapsule suspension prepared by the invention has excellent suspension rate and coating rate and qualified stability. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] Figure 1 :Process flow chart DETAILED DESCRIPTION
[0017] Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making any creative work shall fall within the scope of protection of the present invention.
[0018] The present invention is further explained below in conjunction with specific implementation modes.
[0019] Example 1: Preparation of 5% thiazolyl microcapsules
[0020] Preparation method:
[0021] Preparation of water phase: dissolve the dispersant in deionized water and set aside as the water phase.
[0022] Preparation of oil phase: 5% thiazole phosphine, emulsifier and capsule material (TD I toluene diisocyanate, dosage 5.4%) were dissolved in solvent (solvent oil 150#, dosage 20%) to form an oil phase for use. Under high shear conditions of 8000rpm, the oil phase was uniformly poured into the water phase for shearing for 5 minutes to form a stable oil-in-water (O / W) emulsion at room temperature.
[0023] The stable emulsion was transferred to a 250 mL three-necked flask, and the initiator was dissolved in deionized water. Under stirring conditions, it was uniformly added dropwise to the emulsion for interfacial polymerization reaction (water bath temperature 55°C, stirring rate 400 r / min, water bath time 4 h). After the reaction was completed, thiazolylphosphine microcapsules were obtained.
[0024] Test method:
[0025] Characterization of microcapsule morphology: After the sample to be tested is diluted with distilled water, the encapsulation of the sample is observed under an optical microscope.
[0026] Microcapsule particle size determination: A laser particle size analyzer was used to determine the particle size and particle size distribution of the microcapsules. The D10, D50 and D90 values were used to evaluate the range of the microcapsule particle size distribution, representing the maximum particle size when the cumulative particle size distribution was 10%, 50% and 90%, respectively. D50 is the average particle size of the microcapsules.
[0027] Microcapsule encapsulation rate determination: high performance liquid chromatography was used for determination. Encapsulation rate % = (the amount of thiazolyl fed - the amount of free thiazolyl fed) / the amount of thiazolyl fed * 100.
[0028] Test results:
[0029] In the initial emulsification state of the emulsions using Nongru 500 and Termu l 200 as emulsifiers in standard hard water, oil droplets appeared and a large amount of agglomeration occurred, and the emulsification effect was poor. However, the emulsification effect was good when Lutensol TO8, Termu l 2507 and Ethylan NS-500LQ were used as emulsifiers, and the initial emulsification state of their emulsions in standard hard water was cloudy. Therefore, the above three emulsifiers with good initial emulsification state, Lutensol TO8, Termu l 2507 and Ethylan NS-500LQ, were selected as emulsifiers to prepare microcapsules while other conditions remained unchanged. The appearance of the microcapsules was observed under an optical microscope for screening.
[0030] The encapsulation and agglomeration of microcapsules were observed under an optical microscope: when the emulsifier dosage was determined to be 4%, when Ethylan NS-500LQ was used as the emulsifier, the prepared microcapsules had irregular shapes; when Lutensol TO8 and Termu l 2507 were used as emulsifiers, the prepared microcapsules had good morphology and were spherical. Therefore, Lutensol TO8 and Termu l 2507 were selected as emulsifiers for the microcapsules of highly efficient cyhalothrin.
[0031] Table 1: Effect of emulsifier type on the emulsification effect of thiazolyl microcapsules
[0032] Serial number Emulsifier Emulsification effect 1 Lutensol TO8 excellent 2 Agricultural milk 500 Difference 3 Termul 2507 excellent 4 Ethylan NS-500LQ good 5 Termul 200 Difference
[0033] Three initiators were selected, and the encapsulation of the prepared microcapsules was observed by optical microscopy. When the initiator dosage was determined to be 2.4%, when 1,4-butanediol and ethylenediamine were selected as initiators, the microcapsules had obvious agglomeration and appeared irregular; when PEG400 was selected as the initiator, the microcapsules were well encapsulated, so PEG400 was selected as the initiator for thiazole phosphine microcapsules.
[0034] Table 2: Effect of initiator type on microcapsule formation
[0035] Serial number Dispersants Capsule effect 1 1,4-Butanediol Reunion, irregular 2 PEG400 good 3 Ethylenediamine Reunion, irregular
[0036] When no dispersant is added, the prepared microcapsules have serious agglomeration phenomenon; when the dispersant dosage is determined to be 3%, when dispersants such as sodium lignin sulfonate, calcium dodecylbenzene sulfonate, and Morwet D-425 are added, the prepared microcapsules still have agglomeration phenomenon; when dispersants Atl ox 4913 and Tersperse 2700 are added, the microcapsules are well formed, round, uniform in size, and have no agglomeration phenomenon. This is mainly because the microcapsules are prone to agglomeration. When an appropriate amount of dispersant is added, a certain repulsive force is generated between the microcapsules, making it difficult for the microcapsules to agglomerate. Therefore, Atl ox 4913 and Tersperse 2700 are selected as dispersants for high-efficiency chlorflucythrinate microcapsules.
[0037] Table 3: Effect of emulsifier type on the encapsulation effect of thiazolyl microcapsules
[0038]
[0039]
[0040] The amount of emulsifier was determined to be 4% and the amount of dispersant was 3%. Compared with other combinations, when Lutensol TO8 was selected as the emulsifier and Atl ox 4913 was selected as the dispersant, the D50 of the microcapsule was 2.052 μm and the encapsulation rate was 95.21%.
[0041] Table 4: Effects of different emulsifiers and dispersants on the preparation of thiazolyl microcapsules
[0042]
[0043] The optimal formula of thiazolylphosphine microcapsules was optimized and determined, the solvent was solvent oil 150#, the emulsifier was Lutensol TO8, the capsule material was TDI (toluene diisocyanate), the dispersant was Atlox 4913, the initiator was PEG400, and the water was used to make up the final product.
[0044] Table 5: Formulation of 5% thiazolyl microcapsules
[0045]
[0046]
[0047] Example 2: Preparation of 15% Imidacloprid Suspension
[0048] Preparation method: The imidacloprid suspension is prepared by wet grinding and pulverization process. The type and amount of dispersant in the imidacloprid suspension are screened to prepare a thiamethoxam suspension with good performance. The specific formula is as follows:
[0049] Table 6: 15% Imidacloprid SC formulation
[0050] Element Mass percentage % Imidacloprid 15.0 Atlox 4913 4 Magnesium aluminum silicate 2 Xanthan gum 0.28 SAG1572 0.2 BIT preservative 0.2 water Make up
[0051] Embodiment 3:
[0052] Accurately weigh 5% thiazolyl microcapsules, 15% imidacloprid suspension and other materials (mass ratio 1:1) in a beaker and stir with a magnetic stirrer. See the process flow chart for details.
[0053] Table 7: Formulation of thiamethoxam·imidacloprid ZC
[0054]
[0055]
[0056] The test shows that the microcapsule suspension prepared by the present invention has excellent suspension rate and coating rate, and has qualified stability.
[0057] Table 8: Quality Control Indicators
[0058] Test items index Thiazofosfamide 2.51 Imidacloprid 7.55 pH Range 7.1 Coverage % 95 Suspension rate of thiazolylsulfate % 95.8 Imidacloprid suspension rate % 98.1 Appearance Meet the requirements Thermal storage stability qualified Freeze-thaw stability qualified
[0059] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention, rather than to limit it.
Claims
1. A microcapsule suspension containing thiazolyl and imidacloprid, characterized in that: The invention comprises the following ingredients in percentage by weight: 2-3% of thiathiazolyl technical, 7-8% of imidacloprid technical, 8-12% of solvent oil 150#, 2-3.5% of TDI toluene diisocyanate, 0.8-1.6% of PEG400, 2.5-4.5% of Atlox 4913, 1-3% of Lutensol TO8, 0.05-0.15% of SAG1572, 0.05-0.15% of BIT preservative, 0.5-1.5% of magnesium aluminum silicate, 0.1-0.2% of xanthan gum and water to make up to 100%.
2. The microcapsule suspension containing thiathiazolyl and imidacloprid according to claim 1, characterized in that: The invention comprises the following ingredients in percentage by weight: 2.5% of thiamethoxam technical, 7.5% of imidacloprid technical, 10% of solvent oil 150#, 2.7% of TDI toluene diisocyanate, 1.2% of PEG400, 3.5% of Atlox 4913, 2.0% of Lutensol TO8, 0.1% of SAG1572, 0.1% of BIT preservative, 1% of magnesium aluminum silicate, 0.14% of xanthan gum and water to make up to 100%.
3. A method for preparing a microcapsule suspension containing thiazolyl and imidacloprid as claimed in claim 1 or 2, characterized in that: The following steps are included: Step 1: preparing thiazolyl microcapsules; Step 2: preparing imidacloprid suspension; Step 3: stir and mix thiazolyl microcapsules and imidacloprid suspension in equal mass ratios.
4. The preparation method according to claim 3, characterized in that: The following steps are included: Step 1: Preparation of thiazole phosphine microcapsules: water phase preparation: dissolve part of the dispersant Atlox4913 in water as the water phase for standby use; oil phase preparation: dissolve thiazole phosphine, emulsifier Lutensol TO8 and capsule skin material TDI in solvent solvent oil 150# to form an oil phase for standby use; under high shear conditions, pour the oil phase into the water phase at a uniform speed for shearing to form a stable oil-in-water (O / W) emulsion; transfer the stable emulsion to a three-necked flask, and at the same time dissolve the initiator PEG400 in water, and under stirring conditions, uniformly add it dropwise to the emulsion for interfacial polymerization reaction. After the reaction is completed, thiazole phosphine microcapsules are obtained; Step 2: preparing imidacloprid suspension concentrate: mixing imidacloprid, remaining dispersant Atlox 4913, SAG1572, BIT preservative, magnesium aluminum silicate, and xanthan gum, and preparing thiamethoxam suspension concentrate by wet grinding and pulverization process; Step 3: stir and mix thiazolyl microcapsules and imidacloprid suspension in equal mass ratios.
Citation Information
Cited By
Sustained-release preparation for preventing and treating melon root knot nematode disease in saline-alkali soil and preparation method of sustained-release preparation
CN121336831A
